Biostatistics, Bioinformatics and Clinical Trial Center, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.
Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.
Front Immunol. 2023 Feb 23;14:1082087. doi: 10.3389/fimmu.2023.1082087. eCollection 2023.
The most recent international guidelines regarding recurrent pregnancy loss (RPL) exclude most of the immunological tests recommended for RPL since they do not reach an evidence-based level. Comparisons for metanalysis and systematic reviews are limited by the ambiguity in terms of RPL definition, etiological and risk factors, diagnostic work-up, and treatments applied. Therefore, cohort heterogeneity, the inadequacy of numerosity, and the quality of data confirm a not standardized research quality in the RPL field, especially for immunological background, for which potential research application remains confined in a separate single biological layer. Innovative sequencing technologies and databases have proved to play a significant role in the exploration and validation of cancer research in the context of dataset quality and bioinformatics tools. In this article, we will investigate how bioinformatics tools born for large-scale cancer immunological research could revolutionize RPL immunological research but are limited by the nature of current RPL datasets.
最近关于复发性妊娠丢失(RPL)的国际指南排除了大多数推荐用于 RPL 的免疫检测,因为它们没有达到基于证据的水平。荟萃分析和系统评价的比较受到 RPL 定义、病因和危险因素、诊断方法以及应用的治疗方法的术语不明确的限制。因此,队列异质性、数量不足和数据质量证实了 RPL 领域研究质量的不规范,特别是对于免疫学背景,其潜在的研究应用仍然局限于单个生物学层面。创新的测序技术和数据库已被证明在数据集质量和生物信息学工具的背景下,在癌症研究的探索和验证中发挥了重要作用。在本文中,我们将探讨为大规模癌症免疫学研究而诞生的生物信息学工具如何彻底改变 RPL 免疫学研究,但受到当前 RPL 数据集性质的限制。